The chief executive of rare disease drugmaker Shire Plc on Tuesday suggested that the company could achieve much higher cost savings from its planned $32 billion acquisition of Baxalta than what was announced …
The chief executive of rare disease drugmaker Shire Plc on Tuesday suggested that the company could achieve much higher cost savings from its planned $32 billion acquisition of Baxalta than what was announced …